5-(pyridin-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-(pyridin-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine
• 英文别名: 2-amino-5-(pyridine-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine；5-pyridin-3-yl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-amine
• 化学式: C₁₁H₁₂N₄S
• 分子量: 232.309
• InChiKey: JDOKGDPRJAARIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-((1-methoxypropan-2-yl)oxy)-5-(4-(methylsulfonyl)phenoxy)benzoic acid 、 5-(pyridin-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以36%的产率得到3-((1-methoxypropan-2-yl)oxy)-5-(4-(methylsulfonyl)phenoxy)-N-(5-(pyridin-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)benzamide
  参考文献：
  名称：

  Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

  摘要：

  Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected beta-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.07.051
• 作为产物：
  描述：

  4-哌啶酮缩乙二醇 在 四氢吡咯 、 盐酸 、 palladium diacetate 、 sodium t-butanolate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 水 、 异丙醇 、 甲苯 、 叔丁醇 为溶剂， 反应 16.25h， 生成 5-(pyridin-3-yl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine
  参考文献：
  名称：

  Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

  摘要：

  Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected beta-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.07.051

文献信息

• [EN] TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE<br/>[FR] INHIBITEURS DE LA PHOSPHATIDYLINOSITOL 3-KINASE À BASE DE TÉTRAHYDROTHIAZOLOPYRIDINE
  申请人：VERTEX PHARMA

  公开号：WO2010096389A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds (I) useful as inhibitors of PBK, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及化合物（I），其作为PBK的抑制剂，特别是作为PI3Kγ的抑制剂。该发明还提供了含有这些化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、症状或疾病的方法。
• [EN] N-SUBSTITUTED-3,5-DISUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF<br/>[FR] COMPOSÉ BENZAMIDE N-SUBSTITUÉ-3,5-DISUBSTITUÉ ET SES PROCÉDÉ DE PRÉPARATION ET APPLICATION<br/>[ZH] N-取代-3,5-二取代苯甲酰胺类化合物及其制备方法和应用
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2016112863A1

  公开（公告）日：2016-07-21

  本发明公开一种N-取代-3,5-二取代苯甲酰胺类化合物及其制备方法和应用，该化合物结构如通式I所示，式中，m、X、Y、R1、R2和R3如权利要求书和说明书所示。本发明还公开了包含通式I所示化合的药物组合物。本发明的化合物可以作为葡萄糖激酶激动剂，用于预防和/或治疗与葡萄糖代谢异常相关的疾病。
• Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ
  作者：Philip N. Collier、David Messersmith、Arnaud Le Tiran、Upul K. Bandarage、Christina Boucher、Jon Come、Kevin M. Cottrell、Veronique Damagnez、John D. Doran、James P. Griffith、Suvarna Khare-Pandit、Elaine B. Krueger、Mark W. Ledeboer、Brian Ledford、Yusheng Liao、Sudipta Mahajan、Cameron S. Moody、Setu Roday、Tiansheng Wang、Jinwang Xu、Alex M. Aronov

  DOI：10.1021/acs.jmedchem.5b00498

  日期：2015.7.23

  A series of high,affinity second-generation thiazolopiperidine inhibitors of PI3K gamma were designed based on some general observations around lipid kinase structure. Optimization of the alkylimidazole group led to inhibitors with higher level of PI3K gamma selectivity. Additional insights into PI3K isoform selectivity related to sequence differences in a known distal hydrophobic pocket are also described.